RE: Results30 Apr 2026 10:08
From today's new ARC broker note:
Valuation: After updating our risk-adjusted sum-of-the-parts valuation model for a slight relaxation of the risk ‘haircut’ applied to our NPV of HyProMag Germany following the major milestone of plant opening, and adjusting for Mkango’s recent £12.5m raise, our target valuation moves to 132p/sh. The latter comprises 55p for Mkango’s attributable share of the various HyProMag ventures (equating to a conservative 0.4x NPV) and 76p for Mkango’s interest in the to-be spun-out MKAR primary rare earths business (based on the US$400m valuation of its pro-forma initial shareholding prescribed under the proposed US SPAC transaction). We see scope for upwards rerating of Mkango’s shares towards our target as commerciality is demonstrated at HyProMag UK and Germany, as an investment decision is reached on HyProMag USA, and as the NASDAQ spin-out in the US of MKAR is completed over the coming months. We see considerable upside potential to our valuation if HyProMag expansion plans are progressed and de-risked, while we also note potential for the HMPS technology to be rolled out in other jurisdictions.